Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.

Ana Gómez-Bastero FernándezJuan Francisco Medina GallardoJulio Delgado RomeroAuxiliadora Romero FalcónCristina Benito BernáldezJavier Gallego BorregoFrancisco Javier Alvarez-Gutiérrez

Published in: Journal of asthma and allergy (2022)

Patients diagnosed with severe refractory eosinophilic asthma who experience a partial response with omalizumab or mepolizumab could benefit from switching to benralizumab. This approach can reduce the number of exacerbations, visits to the emergency department, and corticosteroid cycles and improve control of asthma.

Keyphrases

chronic obstructive pulmonary disease
emergency department
lung function
end stage renal disease
allergic rhinitis
chronic kidney disease
ejection fraction
cystic fibrosis
early onset
newly diagnosed
systematic review
chronic rhinosinusitis
drug induced
adverse drug